Navigation Links
Increasing Use of Allergan's Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
Date:12/3/2013

BURLINGTON, Mass., Dec. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the use of Allergan's Botox for the prophylactic treatment of chronic migraine will increase modestly in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan) through 2022, despite lingering clinical and market access hurdles. The drug's expanding role, especially in the United States, coupled with its premium price, will propel its major-market sales for migraine to nearly $850 million in 2022. Greater use of Botox will help drive 4 percent annual growth of the total migraine market—which includes both episodic and chronic migraine—which Decision Resources forecasts will expand from nearly $3.6 billion in 2012 to $5.4 billion in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Migraine finds that the expected launch of two premium-priced nontriptan therapies for the acute treatment of migraine, Allergan's Levadex and CoLucid Pharmaceuticals' 5-HT1F receptor agonist lasmiditan, will also fuel the migraine market growth through 2022. As therapeutic alternatives for triptan nonresponders, patients unable to tolerate triptans, or, in the case of lasmiditan, patients in whom triptans are contraindicated, these agents are expected to earn combined sales accounting for 25 percent of the total migraine market in 2022.

The findings also reveal that the projected launch of APR Applied Pharma Research/tesa Labtec's Zolmitriptan RapidFilm (zolmitriptan oral dispersible film) in additional markets and the launch of four novel triptan reformulations in the United States through 2017 will partially offset generic erosion of this drug class. Emerging reformulations include NuPathe's sumatriptan transdermal patch Zecuity, IntelGenx/RedHill Biopharma's rizatriptan oral film (INT-0008), Avanir Pharmaceuticals/OptiNose's sumatriptan intranasal powder (AVP-825) and Suda's sumatriptan oral spray (SUD-001). Although these niche products are forecast to garner modest patient shares, their combined sales will contribute nearly 15 percent market share at end of our forecast period.

"Although the triptan drug class is crowded and increasingly generic, opportunity exists for alternative acute antimigraine therapies that offer unique mechanisms of action or improved efficacy and/or safety profiles," said Decision Resources Senior Director Bethany A. Kiernan, Ph.D. "At the same time, in the forecasted absence of any new prophylactic therapies, owing in large part to a small development pipeline, improved prophylactic therapies remain one of the greatest unmet needs in migraine treatment."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Increasing Incidence of Cardiovascular Diseases to Drive The Cardiovascular Devices Market in Emerging Countries
2. Pharma Execs Continue Looking For Growth Opportunities In Spite Of Increasing Regulatory Challenges: KPMG Survey
3. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
4. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
5. Patient Monitoring Devices Market to 2017 - Increasing Use of Wireless Remote Patient Monitoring to be the Key Technology Trend
6. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
7. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
8. Patient Monitoring Devices Market in Emerging Countries (China, India, Brazil) to 2017 - Increasing Government Spending and Foreign Direct Investment (FDI) to Drive Future Growth
9. RMANJ Research Demonstrates That Egg Freezing Prior To IVF Yields Positive Outcomes Without Increasing Risk Of Aneuploidy
10. Global Hospital Supplies Market to 2018 - Increasing Preference for Electro-mechanical Tables over Conventional Hydraulic Models to Drive Market Growth: MarketResearchReports.Biz
11. AssureRx Health Expands Management Team to Support Increasing Business Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- 7D Surgical announced today that it has ... and Drug Administration (FDA) and a medical device ... commercial launch of its innovative Machine-vision Image Guided ... Surgical System.  The 7D Surgical ... vision algorithms to eliminate the long-standing barriers to ...
(Date:1/23/2017)... WASHINGTON , Jan. 23, 2017 The ... of the Pharmacy and Medically Underserved Areas ... House of Representatives. The legislation, which was previously introduced ... improve patient access to health care through pharmacists and ... bill include Representatives Brett Guthrie (R-KY), ...
(Date:1/23/2017)... 23, 2017 Stock-Callers.com today presents the ... CPRX ), Sophiris Bio Inc. (NASDAQ: ... and Agile Therapeutics Inc. (NASDAQ: AGRX ). These ... lower in late trade on Friday, January 20 th , ... while shares of health care companies in the S&P 500 ...
Breaking Medicine Technology:
(Date:1/23/2017)... TAMPA, Fla. (PRWEB) , ... January 23, 2017 ... ... for the nonprofit educational institution’s inaugural K-20 Education Summit to be held March ... proposals to present by Jan. 25, 2017. , The keynote speakers include Dr. ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... Dc (PRWEB) , ... January 23, 2017 , ... ... American University is taught by healthcare management and evaluation leaders with decades of ... fee-for-service to pay-for-value in the United States healthcare system, there is a renewed ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... in North America for the scientific development, healthcare training and clinical application of ... and its 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , For ...
(Date:1/23/2017)... ... January 23, 2017 , ... METTLER TOLEDO ... Process Chemistry by Applying Simple PAT Tools . , Crystallization is ... purify the desired product. Chemists now spend more time developing better intermediate ...
Breaking Medicine News(10 mins):